ASCT conditioning

Phase 3Small molecule

PProf. Dr. M. Dreyling (co-chairman)

ASCT conditioning is one of 51 small molecule programs targeting Mantle Cell Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Mantle Cell LymphomaRecruiting

Mantle Cell LymphomaPhase 3

Recruiting

Competition

Competitive Landscape

51 competitors in Mantle Cell Lymphoma

#DrugCompanyPhaseTrials

Rituxan

Roche

Approved

77 2

Cytosar

Teva

Approved

22 3

Calquence

AstraZeneca

Approved

16 4

Cytoxan

BBaxter Healthcare Corporation

Approved

31 5

Oncovin

Eli Lilly

Approved

11 6

Adriamycin

Pfizer

Approved

9 7

Decadron

AAspen Global Incorporated

Approved

17 8

Thalomid

Bristol-Myers Squibb

Approved

3 9

Rayos

RRoxane Laboratories

Approved

9 10

Vepesid

AAvyxa

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Mantle Cell Lymphoma1 trial

ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

Recruiting·PProf. Dr. M. Dreyling (co-chairman)·Phase 3·NCT02858258·870 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ASCT conditioning. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ASCT conditioning compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ASCT conditioning. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Prof. Dr. M. Dreyling (co-chairman) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: PProf. Dr. M. Dreyling (co-chairman)

ASCT conditioning

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Mantle Cell Lymphoma1 trial

References

Drug Info

Quick Facts

Related News